Billionaire hedge fund and NY Mets owner, Steve Cohen amped up his support for psychedelics R&D through a new investment of nearly $19 million in beneficially owned shares of Cybin Inc. (NYSE: CYBN).

The considerably large acquisition puts Cybin in the limelight with credibility status in ongoing and future work (see Cybin’s recent acquisition announcement of DMT therapeutics developer Small Pharma (OTCMKTS: DMTTF). 

Together with his wife Alexandra, the Wall Street tycoon has been funding groundbreaking projects with these compounds in past years to the tune of over $31 million in donations

The couple’s foundation has been one of the largest donors to MAPS’ MDMA clinical research, which recently published new, highly encouraging results for PTSD treatment.

The shares, purchased through Cohen’s Point72 asset management firm, add to the institutional investment the sector recently received and its further validation. 

Owning over $26 billion in assets, the firm shared the purchase of …

Full story available on

A note to our visitors

This website has updated its privacy policy in compliance with changes to European Union data protection law, for all members globally. We’ve also updated our Privacy Policy to give you more information about your rights and responsibilities with respect to your privacy and personal information. Please read this to review the updates about which cookies we use and what information we collect on our site. By continuing to use this site, you are agreeing to our updated privacy policy.